× We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click our cookies policy for information on how to change your cookie settings.


meta|Evidence - COVID-19

Live meta-analysis and evidence synthesis of therapies for COVID19  

tutorial video
En     Fr

Our approach

RSS

enable push notifications

     
Treament Trials
Demonstrated or suggested benefit Inconclusive results Uncertain results Safety results
20

statistically conclusive 8 % decrease in deaths

suggested 19 % decrease in ventilation

inconclusive results for: deaths (time to event analysis only); clinical deterioration; clinical improvement; clinical improvement (14-day); clinical improvement (time to event analysis only); death or ventilation; hospital discharge; ICU admission; serious adverse events; superinfection--
5

suggested 36 % decrease in deaths

statistically conclusive 30 % increase in clinical improvement

suggested 49 % increase in clinical improvement (14-day)

suggested 45 % increase in clinical improvement (28-day)

suggested 29 % increase in clinical improvement (7-day)

suggested 22 % increase in clinical improvement (time to event analysis only)

suggested 33 % decrease in serious adverse events

suggested 42 % decrease in elevated liver enzymes

inconclusive results for: deaths (time to event analysis only); death or ventilation; ventilation; time to recovery; AE leading to drug discontinuation; adverse events; deep vein thrombosis; hyperbilirubinemia; pulmonary embolism; renal impairment--
42 noneinconclusive results for: deaths; deaths (time to event analysis only); clinical deterioration; clinical improvement; clinical improvement (14-day); clinical improvement (28-day); clinical improvement (time to event analysis only); death or ventilation; hospital discharge; hospitalization; radiologic improvement (7-day); ventilation; ventilation (time to event analysis only); viral clearance ; viral clearance (time to event analysis only); viral clearance by day 14; viral clearance by day 7; ICU admission; cardiac arrest; adverse events--
21

statistically conclusive 52 % decrease in clinical deterioration

inconclusive results for: death or transfer to ICU; deaths; deaths (time to event analysis only); clinical improvement; clinical improvement (28-day); death or ventilation; ventilation; viral clearance by day 7; ICU admission; off oxygenation; serious adverse events--
13

suggested 2.3-fold increase in clinical improvement

suggested 3.2-fold increase in clinical improvement (28-day)

statistically conclusive 2.2-fold increase in clinical improvement (time to event analysis only)

statistically conclusive 4.1-fold increase in viral clearance by day 7

suggested 2.2-fold increase in time to recovery

inconclusive results for: deaths; deaths (time to event analysis only); clinical deterioration; death or ventilation; hospital discharge; hospitalization; ventilation; viral clearance (time to event analysis only); ICU admission; off oxygenation; serious adverse events; superinfection; adverse events--
24

statistically conclusive 26 % increase in clinical improvement

statistically conclusive 19 % decrease in death or ventilation

inconclusive results for: death or transfer to ICU; deaths (time to event analysis only); clinical deterioration; clinical improvement (28-day); clinical improvement (time to event analysis only); hospital discharge; ventilation; ICU admission; serious adverse events; superinfection; adverse events-

statistically conclusive 11 % decrease in deaths with safety concern

6

statistically conclusive 31 % increase in clinical improvement

suggested 86 % increase in clinical improvement (14-day)

inconclusive results for: deaths; deaths (time to event analysis only); clinical improvement (time to event analysis only); serious adverse events; adverse events--
5

suggested 53 % decrease in ventilation

inconclusive results for: deaths; hospitalization for COVID19 or death; clinical deterioration; hospitalization; ICU admission; related AE (TRAE); serious adverse events--
3 noneinconclusive results for: deaths; clinical improvement; Major thrombotic events or death; Major bleeding--
1 noneinconclusive results for: deaths; Major bleeding; Thromboembolic events--

Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant

This project is supported by a grant of the French Ministry of Health (Hospital Clinical Research Program, PHRC-N), Université de Lyon (UdL/Idex), and self-funded by Hospices Civils de Lyon, CNRS UMR5558 LBBE University Lyon-1.

     

- About - Our approach - Credits - RSS Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons